Arrowhead Pharmaceuticals, Inc. ARWR
65.92
(0.15)
(0.23%)
as of 25 Sep
- Market cap
- $9.3B
- P/E
- 0.0×
Follow ARWR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 43.39 | 0.00 | 0.00 |
P/S ratio |
5.56 | 8.34 | 14.36 | 17.46 | |
P/FCF ratio |
29.41 | 28.25 | 0.00 | 0.00 | |
P/Operating CF |
225.14 | 674.88 | 105.75 | (65.85) | |
P/B ratio |
9.16 | 16.17 | 14.91 | 25.08 | |
Price to Tangible BV |
9.29 | 16.36 | 15.06 | 25.38 | |
EV/Sales |
4.76 | 7.69 | 12.91 | 16.35 | |
EV/EBITDA |
33.90 | 26.21 | 0.00 | 0.00 | |
EV/Operating CF |
21.99 | 24.71 | (221.09) | (185.40) | |
EV/FCF |
25.17 | 26.04 | (157.79) | (145.77) | |
Quick Ratio |
4.74 | 3.27 | 6.10 | 5.68 | |
Current Ratio |
4.86 | 3.38 | 6.23 | 5.90 | |
Net Debt/EBITDA |
(13.49) | (15.12) | 6.60 | 4.49 | |
Debt/Assets |
18.40% | 12.66% | 38.87% | 40.91% | |
Debt/Equity |
0.51 | 0.36 | 1.47 | 1.85 | |
Asset Turnover |
0.66 | 0.83 | 0.32 | 0.38 | |
Operating CF/Net income |
(0.86) | 0.44 | (0.64) | 0.91 | |
Capex/Depreciation |
(1.46) | (0.34) | (0.57) | (0.66) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
68.11% | 67.11% | 234.96% | 263.41% | |
Selling, General and Administrative Expense of Revenue |
14.69% | 17.43% | 56.61% | 62.62% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.44% | 7.34% | 22.61% | 19.76% | |
Graham Net Nets |
0.01 | 0.01 | 0.02 | 0.00 | |
Graham Number |
0.00 | 11.89 | 0.00 | 0.00 | |
Earnings Yield |
(0.23%) | 2.30% | (3.43%) | (2.76%) | |
Free Cash Flow Yield |
3.40% | 3.54% | (0.57%) | (0.64%) | |
Revenue per Share |
1.92 | 1.93 | 0.52 | 0.52 | |
Operating CF per Share |
0.15 | 0.10 | 0.59 | (1.24) | |
Capex per Share |
(0.06) | (0.02) | (0.02) | (0.03) | |
Free Cash Flow per Share |
0.10 | 0.08 | 0.57 | (1.26) | |
Cash per Share |
6.87 | 6.69 | 12.53 | 11.17 | |
Shareholders Equity per Share |
3.76 | 4.11 | 4.21 | 3.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.76 | 4.11 | 4.21 | 3.25 | |
Free Cash Flow |
13.00 | 11.33 | 81.88 | (181.32) | |
Working Capital |
755.15 | 826.96 | 1,544.53 | 1,388.07 | |
Capital Expenditures |
(7.49) | (2.15) | (2.56) | (3.85) | |
Net Current Asset Value |
68.76 | 132.91 | 170.40 | 25.44 | |
EV/EBIT |
40.15 | 27.90 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.03 | 0.05 | |
Net Profit Margin |
(9.26%) | 11.67% | (180.01%) | (258.17%) | |
Price to Operating Income |
46.91 | 30.27 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.04 | 110.69 | 9.03 | 9.13 | |
Average Payables |
14.53 | 23.70 | 20.36 | 30.41 | |
Average Assets |
1,262.55 | 1,308.94 | 1,920.88 | 1,746.31 | |
Average Common Equity |
347.24 | 309.39 | 641.57 | 492.92 |
Columns are period end dates